ASCENDIS PHARMA A/S: Financial statements 2022
CVR: 29918791
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
ASCENDIS PHARMA A/S (CVR 29918791) has filed annual accounts for 2022. In 2022, the company reported revenue of EUR 51,174,000 and a net result of EUR -583,194,000 compared with EUR -383,577,000 the year before. That is an increase of 557.9% compared with the year before. The profit margin was -1,139.6%. Equity in the 2022 report amounted to EUR 263,348,000. The solvency ratio was 24.2%. The company had 719 employees in the financial year.
- Revenue
- EUR 51,174,000
- Gross Profit
- EUR 39,037,000
- Profit/Loss
- EUR -583,194,000
- Equity
- EUR 263,348,000
- Total Assets
- EUR 1,089,738,000
- Employees
- 719
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 51.2 mio. EUR | 39 mio. EUR | -583.2 mio. EUR | 263.3 mio. EUR | 719 |
| 2021 | 7.8 mio. EUR | 4.3 mio. EUR | -383.6 mio. EUR | 883.6 mio. EUR | - |
| 2020 | 7 mio. EUR | - | -419 mio. EUR | 838.7 mio. EUR | - |
| 2019 | 13.4 mio. EUR | - | -218 mio. EUR | 597.1 mio. EUR | - |
| 2018 | 10.6 mio. EUR | - | -130.1 mio. EUR | 280.1 mio. EUR | - |
Official annual report
Keep an eye on ASCENDIS PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of September 9, 2022, Siham Imani has joined the board of directors of ASCENDIS PHARMA A/S.
As of September 9, 2022, William Carl Fairey Jr has joined the board of directors of ASCENDIS PHARMA A/S.
ASCENDIS PHARMA A/S has published its annual report for 2021. Revenue came to DKK 7,778,000, and the net result was DKK -383,577,000.
As of May 30, 2022, Jim Healy has left the board of directors of ASCENDIS PHARMA A/S.
About ASCENDIS PHARMA A/S
ASCENDIS PHARMA A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA ApS and CADENZA PARTNERS ApS. The management consists of Jan Møller Mikkelsen, Anni Lotte Kirstine Pedersen and Michael Wolff Jensen. The board consists of Albert Cha (chair), Jan Møller Mikkelsen, Jean-Jacques Bienaime and Lars Holtug. The company is owned by Cede & Co. The company has 688 employees (2026). In 2025, the company reported revenue of EUR 720,132,000 and a net result of EUR -228,034,000 compared with EUR -378,084,000 the year before. Equity in the 2025 report amounted to EUR -162,821,000.